Evidence map›Paper›PMID 40662350›Full record

ArticleThoracic cancer2025

Planning Target Volume and Nodal Status Predict Clinical Outcomes After Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer.

Ori Aslan, Johnathan Arnon, Itamar Averbuch, Daniel Reinhorn, Hovav Nechushtan, Yakir Rottenberg, Philip Blumenfeld

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ori AslanDepartment of Military Medicine and "Tzamert," Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID https://orcid.org/0009-0005-8772-251X
Johnathan ArnonSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0002-5688-5712
Itamar AverbuchRabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.ORCID https://orcid.org/0000-0003-1784-4528
Daniel ReinhornRabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.ORCID https://orcid.org/0000-0002-7717-9032
Hovav NechushtanSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Yakir RottenbergSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0002-5838-8867
Philip BlumenfeldSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0003-4672-6862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnresectable Stage III non-small cell lung cancer (NSCLC) presents a major clinical challenge due to its heterogeneous nature and poor prognosis. Despite aggressive treatment with concurrent chemoradiation (CRT) and the introduction of Durvalumab consolidation therapy, the risk of recurrence remains high, necessitating research into predictors of clinical outcomes.

methodsIn this retrospective, two-center study, we reviewed cases of 141 patients with Stage III unresectable NSCLC, treated with CRT followed by Durvalumab between 2017 and 2023. We retrieved clinical and treatment characteristics and analyzed associations with clinical outcomes.

resultsUtilizing a binary threshold for planning target volume (PTV), patients with PTV ≥ 350 cm

conclusionsThis study identifies PTV ≥ 350 cm

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAntineoplastic Agents, ImmunologicaldurvalumabchemoradiationDurvalumabnodal statusnon‐small cell lung cancer (NSCLC)planning target volume (PTV)

Identifiers

PMID40662350
PMCPMC12260756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.